Cancer Care


A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects with Metastatic Renal Cell Carcinoma
Principal Investigator (?)
Study Number
The purpose is to determine the safety, effectiveness and best dose to use when giving
Nivolumab in combination with Sunitinib, Pazopanib, or Ipilimumab for the treatment of
metastatic renal cell carcinoma.
Phase (?)
Phase I
Sponsor (?)
Available at the following location(s)


View more details from

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.